Phase II Study of Intravenous Rexin-G in Osteosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

June 30, 2011

Conditions
Osteosarcoma
Interventions
GENETIC

Rexin-G Dose 1

Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity

GENETIC

Rexin-G Dose 2

Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity

Trial Locations (1)

91108

Epeius Clinical Research Unit/Sarcoma Oncology Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Epeius Biotechnologies

INDUSTRY